soul trial semaglutide SOUL: Oral Bests Usual Care in High-Risk Type 2 Diabetes Projected impact of oral semaglutide

gut problems Every weight loss medication comes with trade-offs

When caloric intake drops below the body's baseline needs, energy levels naturally decline

Danuglipron, Pfizer's oral GLP-1 agonist, has had a more challenging development path, with an initial twice-daily formulation producing significant nausea rates that led to reformulation as a once-weekly oral tablet

Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study

Similarly, companies need to make data-driven decisions about divesting from product lines that may face declining demand in a GLP-1-influenced market

It physically destroys the bacterial membrane